NasdaqCM - Nasdaq Real Time Price USD

ClearPoint Neuro, Inc. (CLPT)

14.11

-0.14

(-0.98%)

At close: May 9 at 4:00:02 PM EDT

14.15

+0.04

+(0.28%)

After hours: May 9 at 4:58:24 PM EDT

ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI

SOLANA BEACH, CA / ACCESS Newswire / April 28, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announces that today its partner, ...

ACCESS Newswire 12 days ago

CLPT
-0.98%
The five-year returns have been incredible for ClearPoint Neuro (NASDAQ:CLPT) shareholders despite underlying losses increasing

While ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shareholders are probably generally happy, the stock hasn't had...

Simply Wall St. 13 days ago

CLPT
-0.98%
ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025

SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release ...

ACCESS Newswire 15 days ago

CLPT
-0.98%
ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 - Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room

The platform will be showcased at the American Academy of Neurological Surgeons Annual Meeting in Boston on April 25-28, 2025. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / April 24, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global ...

ACCESS Newswire 16 days ago

CLPT
-0.98%
Here's Why We're Not Too Worried About ClearPoint Neuro's (NASDAQ:CLPT) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. last month

CLPT
-0.98%
ClearPoint Neuro Full Year 2024 Earnings: Misses Expectations

ClearPoint Neuro ( NASDAQ:CLPT ) Full Year 2024 Results Key Financial Results Revenue: US$31.4m (up 31% from FY 2023...

Simply Wall St. 2 months ago

CLPT
-0.98%
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Analysts Are Pretty Bullish On The Stock After Recent Results

There's been a notable change in appetite for ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares in the week since its...

Simply Wall St. 2 months ago

CLPT
-0.98%
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results

Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling ...

ACCESS Newswire 2 months ago

CLPT
-0.98%
While institutions own 33% of ClearPoint Neuro, Inc. (NASDAQ:CLPT), individual investors are its largest shareholders with 59% ownership

Key Insights Significant control over ClearPoint Neuro by individual investors implies that the general public has more...

Simply Wall St. 2 months ago

CLPT
-0.98%
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025

SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will ...

ACCESS Newswire 2 months ago

CLPT
-0.98%
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) approval for ...

ACCESS Newswire 2 months ago

CLPT
-0.98%
ClearPoint Neuro price target raised to $20 from $15 at B. Riley

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating on the shares. ClearPoint Neuro on Monday announced FDA clearance of its Version 3.0 Navigation Software, which expands the platform’s capabilities to include CT-guided procedures in the operating room, in addition to its existing MRI-guided functionality, the analyst tells investors in a research note. This new functionality will streamline workflows for healthcare provi

TipRanks 3 months ago

CLPT
-0.98%
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory

We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on Twitter by northeasternsvf. In this article, we will summarize the bulls’ thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)’s share was trading at $17 as of Jan 27th. ClearPoint Neuro (CLPT) is strategically positioned in the rapidly growing neuro-therapy market, offering a critical, mission-specific navigation platform […]

Insider Monkey 3 months ago

CLPT
-0.98%
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its ClearPoint Navigation Software ...

ACCESS Newswire 3 months ago

CLPT
-0.98%
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform ...

ACCESS Newswire 5 months ago

CLPT
-0.98%
The ClearPoint Neuro, Inc. (NASDAQ:CLPT) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Last week, you might have seen that ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) released its third-quarter result to the...

Simply Wall St. 5 months ago

CLPT
-0.98%
ClearPoint Neuro Reports Third Quarter 2024 Results

Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company ...

ACCESS Newswire 5 months ago

CLPT
-0.98%
Those who invested in ClearPoint Neuro (NASDAQ:CLPT) five years ago are up 213%

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...

Simply Wall St. 5 months ago

CLPT
-0.98%
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and ...

ACCESS Newswire 6 months ago

CLPT
-0.98%
ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2024 third quarter on Thursday, November 7th at 4:30 p.m

GlobeNewswire 6 months ago

CLPT
-0.98%

Performance Overview

Return	CLPT	S&P 500 (^GSPC)
YTD	-8.26%	-3.77%
1-Year	+130.93%	+8.55%
3-Year	+91.19%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ClearPoint Neuro, Inc. (CLPT)

ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI

The five-year returns have been incredible for ClearPoint Neuro (NASDAQ:CLPT) shareholders despite underlying losses increasing

ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025

ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 - Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room

Here's Why We're Not Too Worried About ClearPoint Neuro's (NASDAQ:CLPT) Cash Burn Situation

ClearPoint Neuro Full Year 2024 Earnings: Misses Expectations

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Analysts Are Pretty Bullish On The Stock After Recent Results

ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results

While institutions own 33% of ClearPoint Neuro, Inc. (NASDAQ:CLPT), individual investors are its largest shareholders with 59% ownership

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025

ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula

ClearPoint Neuro price target raised to $20 from $15 at B. Riley

ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory

ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0

ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

The ClearPoint Neuro, Inc. (NASDAQ:CLPT) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

ClearPoint Neuro Reports Third Quarter 2024 Results

Those who invested in ClearPoint Neuro (NASDAQ:CLPT) five years ago are up 213%

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

Performance Overview